CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.09.26.21264023: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: However, the original trial protocols for data collection were reviewed and approved by the local review boards or ethics committees at each study centre for the ocrelizumab phase II trial [NCT00676715. 79 Centres], the phase III cladribine tablet study [NCT00213135. 155 centres] and the alemtuzumab [NCT00530348.
Consent: All patients provided written informed consent [Kappos et al. 2011, Giovannoni et al. 2010, Cohen et al. 2012, Coles et al. 2012].Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Lymphocyte and CD19 peripheral blood CD19 B cell data related to … SciScore for 10.1101/2021.09.26.21264023: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: However, the original trial protocols for data collection were reviewed and approved by the local review boards or ethics committees at each study centre for the ocrelizumab phase II trial [NCT00676715. 79 Centres], the phase III cladribine tablet study [NCT00213135. 155 centres] and the alemtuzumab [NCT00530348.
Consent: All patients provided written informed consent [Kappos et al. 2011, Giovannoni et al. 2010, Cohen et al. 2012, Coles et al. 2012].Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Lymphocyte and CD19 peripheral blood CD19 B cell data related to the licenced 12mg dose was extracted from the CARE-MS trials, using SAS software. SASsuggested: (SASqPCR, RRID:SCR_003056)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT00676715 Active, not recruiting A Study of the Efficacy and Safety of Ocrelizumab in Patient… NCT00213135 Completed A Safety and Efficacy Study of Oral Cladribine in Subjects W… NCT00530348 Completed Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sc… NCT00548405 Completed Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sc… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
